NCT00518297 - DDI HV (ATV - Merck) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

December 31, 2007

Study Completion Date

December 31, 2007

Conditions

HIV Infections

Interventions

DRUG

Raltegravir

Tablet, Oral, 400 mg, twice daily for 5 Days

DRUG

Atazanavir

Capsule, Oral, 300 mg, twice daily for 7 Days

DRUG

Atazanavir + Raltegravir

Capsule/Tablet, Oral, 300/400, twice daily for 14 Days

Trial Locations (1)

Bristol-Myers Squibb Clinical Pharmacology Unit, Hamilton